BiotechTube
Helicore Biopharma

Helicore Biopharma

Cambridge, United States· Est.
helicore.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $65M

Overview

Helicore Biopharma is a private, preclinical-stage biotech developing a novel antibody therapeutic targeting the GIP hormone for the treatment of obesity and related metabolic disorders. Its differentiated strategy involves directly binding and neutralizing the circulating GIP ligand, aiming to block its action in both peripheral tissues and the central nervous system to reduce body weight and improve metabolic health. The company is backed by a seasoned management team and leading life science venture capital firms, including OrbiMed, Versant Ventures, and Longitude Capital. Helicore is positioned in the high-growth obesity therapeutics market but faces significant risks typical of early-stage drug development.

ObesityMetabolic Disease

Technology Platform

Therapeutic antibody platform for high-affinity neutralization of soluble protein ligands, specifically targeting the GIP hormone.

Funding History

1
Total raised:$65M
PIPE$65M

Opportunities

The global obesity therapeutics market is massive and growing, validated by GLP-1 agonists, creating demand for novel mechanisms.
Helicore's first-in-class GIP ligand-binding approach offers a differentiated strategy that could be effective as a monotherapy or in future combination regimens.
Success would position the company as an attractive acquisition target for large pharma players seeking to bolster their metabolic disease portfolios.

Risk Factors

The core scientific hypothesis that GIP antagonism treats obesity remains unproven in humans.
The company faces intense competition from advanced clinical-stage programs, including GLP-1/GIP dual agonists.
As a preclinical, single-asset company, Helicore's entire value is binary on the success of its lead program, facing significant development, regulatory, and financing risks.

Competitive Landscape

Helicore operates in the highly competitive obesity drug market, competing directly with companies like Eli Lilly (tirzepatide - a GLP-1/GIP dual agonist) and Novo Nordisk, as well as numerous biotechs developing next-generation incretin therapies. Its unique ligand-binding approach differentiates it from receptor antagonists but lags behind clinical-stage assets. It must demonstrate superior or complementary efficacy to established mechanisms to capture market share.

More companies in Biologics / Biosimilars →More companies in United States →